Alvogen has acquired marketing rights to the Alvesco cliclesonide metered dose inhaler in a number of Central and Eastern European (CEE) countries from Covis Pharma, the company said. Terms of the deal, which includes Bulgaria, Czech Republic, Hungary, Kazakhstan, Latvia, Poland, Romania, Russia and Slovakia, were not disclosed.
In November 2018, Covis announced that it had paid AstraZeneca $350 million up front for the ex-US rights to Alvesco, Omnaris ciclesonide nasal spray Omnaris, and Zetonna ciclesonide nasal MDI. Covis had previously acquired US rights to those products from Sunovion in 2017.
Alvogen VP, CEE, Hacho Hatchikian commented, “We are excited by the market opportunity that Alvesco has to offer and we look forward to expanding our respiratory portfolio in the CEE region and provide patients and physicians with high-quality treatments. With a sales and marketing network covering more than 20 CEE markets and 450 sales representatives, we are well positioned to continue to grow our respiratory business in the region.”
Covis Pharma General Manager, Europe & ROW, Steen Vangsgaard said, “We are thrilled to partner with Alvogen for the commercialization and distribution of Alvesco in CEE. Alvogen’s ambition within respiratory in combination with their dedication to quality treatments and relentless business execution is a great match with Covis’ ambition and ethos. Together we will do a wonderful job securing patients access to Alvesco.”
Read the Alvogen press release.
